Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Wugen Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed among 3 distinct examiners and 3 distinct art units, indicating separate examination tracks within the portfolio.
AEDER, SEAN E is the busiest examiner, with 1 pending matter. Counsel should coordinate the overall technical and claim strategy while managing each response independently, since the recorded examiner and art-unit assignments are separate.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTIN, AMY MARIE | 1 | 71.4% | +45.9% |
| AEDER, SEAN E | 1 | 57.0% | +20.0% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 72.1% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412163 | EXPANSION OF MEMORY NATURAL KILLER CELLS | CHATTIN, AMY MARIE | — |
| 18484253 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | DUNN, LINDSAY MICHELLE | — |
| 18447138 | POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18412163 | EXPANSION OF MEMORY NATURAL KILLER CELLS | CHATTIN, AMY MARIE | — |
| 18501908 | GENERATION OF CD3 EXPRESSING IMMUNE CELLS FOR USE IN CONJUNCTION WITH CD3 BINDING BISPECIFIC TARGETING AGENTS | AEDER, SEAN E | — |
| 18447138 | POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE | EDGINGTONGIORDANO, FRANCESCA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1642 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18412163 | EXPANSION OF MEMORY NATURAL KILLER CELLS | CHATTIN, AMY MARIE | 1643 | §102§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18501908 | GENERATION OF CD3 EXPRESSING IMMUNE CELLS FOR USE IN CONJUNCTION WITH CD3 BINDING BISPECIFIC TARGETING AGENTS | AEDER, SEAN E | 1642 | §103 | Final Rejection | — | Pending | Nov 03, 2023 |
| 18484253 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | DUNN, LINDSAY MICHELLE | 1644 | §102§103§112 | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18447138 | POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWugen Inc. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.
Amy Marie Chattin has the most, with 1 of Wugen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.